Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 1 Sell Rating(s), 7 Hold Rating(s), 9 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $29.16 (11.21% upside)

Current Analysts' Coverage Summary for Sarepta Therapeutics (NASDAQ:SRPT)
Show:
DateFirmActionRatingPrice TargetActions
5/22/2015WBB SecuritiesBoost Price TargetStrong-Buy$25.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/21/2015Vetr Inc.DowngradeBuy -> Sell$29.40View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/21/2015Bank of AmericaDowngradeBuy -> Neutral$20.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015OppenheimerSet Price TargetBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Cowen and CompanyReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Robert W. BairdBoost Price TargetBuy$20.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015WedbushBoost Price TargetNeutral$16.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Canaccord GenuityUpgradeHold -> Buy$16.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015SunTrustUpgradeNeutral -> Buy$14.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015RBC CapitalBoost Price TargetSector Perform$15.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Roth CapitalBoost Price TargetBuy$22.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2015Needham & Company LLCReiterated RatingBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2015ZacksUpgradeSell -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2014Stifel NicolausDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2014JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2014Credit SuisseReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/30/2014Deutsche BankReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/22/2014Citigroup Inc.UpgradeSell -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/21/2014William BlairUpgradeMarket Perform -> Outperform$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2014SidotiInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/23/2013Piper JaffrayUpgradeUnderweight -> Neutral$19.55 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2013Leerink SwannLower Price TargetMarket Perform$44.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2013FBR & Co.Lower Price TargetMarket Perform$48.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2013Janney Montgomery ScottDowngradeNeutral -> SellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2013Burrill Institutional ResearchDowngradeOutperform -> Market Perform$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/22/2013 forward)